Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Cost efficiency and formulary considerations for statin therapy.

Killilea T, Funk L.

Am J Manag Care. 2006 Oct;12(11 Suppl):S325-31.

3.

Statin and ezetimibe combination therapy in cardiovascular disease.

Dembowski E, Davidson MH.

Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):183-8. doi: 10.1097/MED.0b013e3283295297. Review.

PMID:
19262375
4.

[Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].

Vaverkov√° H.

Vnitr Lek. 2007 Apr;53(4):421-7. Review. Czech.

PMID:
17578178
5.

Perspectives on low-density lipoprotein cholesterol goal achievement.

Catapano AL.

Curr Med Res Opin. 2009 Feb;25(2):431-47. doi: 10.1185/03007990802631438 . Review.

PMID:
19192988
6.
7.

A review of lipid management in primary and secondary prevention.

Dembowski E, Davidson MH.

J Cardiopulm Rehabil Prev. 2009 Jan-Feb;29(1):2-12. doi: 10.1097/HCR.0b013e318192754e. Review.

PMID:
19158581
8.

Low-density lipoprotein cholesterol reduction: the end is more important than the means.

LaRosa JC.

Am J Cardiol. 2007 Jul 15;100(2):240-2. Epub 2007 May 24. Review.

PMID:
17631077
9.
10.

Expanding options with a wider range of rosuvastatin doses.

Olsson AG.

Clin Ther. 2006 Nov;28(11):1747-63. Review.

PMID:
17212997
11.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
12.
13.

Statins and C-reactive protein levels.

Asher J, Houston M.

J Clin Hypertens (Greenwich). 2007 Aug;9(8):622-8. Review.

14.
15.
16.
17.
18.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
19.

Determinants of the cost-effectiveness of statins.

Morrison A, Glassberg H.

J Manag Care Pharm. 2003 Nov-Dec;9(6):544-51. Review.

20.

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

O'Keefe JH, Carter MD, Lavie CJ, Bell DS.

Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Review.

PMID:
19491548
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk